Podium to Practice: Chicago 2025 – GI: CheckMate 577

Podium to Practice: Chicago 2025 – GI: CheckMate 577

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sharlene Gill

Icon Chair Speaker

Speakers

Dr. Rachel Goodwin

Dr. Florian Lordick

Studies / Trials Discussed

4000 – Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.

Studies/trials discussed:

4000 – Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.
Tagged